In this study, we tested the hypothesis that hypoxic pulmonary vasoconstriction may be enhanced in systemic hypertension. The hypothesis took origin from the following two considerations: alveolar hypoxia constricts the pulmonary vessels by enhancing the Ca2+ penetration across sarcolemma of the smooth muscle cells and systemic high blood pressure is associated with an elevation of tone and reactivity of the lung vessels, which seems to depend on an excessive cytosol free Ca21 concentration due to alterations in sodium handling and in the Na+-Ca2' exchange system. These considerations suggest the possibility that the disorders in the biochemistry of smooth muscle contraction in hypertension facilitate the rise of cytosol Ca2' concentration during alveolar hypoxia, thus resulting in a potentiation of the vasoconstrictor properties of this stimulus. In 43 hypertensive and 17 normotensive men, pulmonary arteriolar resistance has been evaluated during air respiration and after 15 minutes of breathing 17%, 15%, and 12% oxygen in nitrogen. Curves relating changes in pulmonary arteriolar resistance to oxygen breathing contents had similar configuration in the two populations but in hypertension were steeper and significantly shifted to the left, reflecting a lower threshold and an enhanced reactivity. This pattern was not related to differences in severity of the hypoxic stimulus, plasma catecholamine concentration, or hypocapnia and respiratory alkalosis induced by hypoxia and probably was not mediated through a-receptor activation. Calcium channel blockade with nifedipine was able to almost abolish both the normotensive and the hypertensive pulmonary vasoconstricting reaction. These findings support the hypothesis that hypoxic pulmonary vasoconstriction may be enhanced in systemic hypertension. As to the mechanism of this effect, findings are consistent with the interpretation that hypoxic vasomotion is mediated by an increased availability of calcium ions for the contractile elements of the lung vessels, which is facilitated with hypertension. The association of high blood pressure with enhanced pulmonary vasoreactivity to alveolar hypoxia could have clinical implications in patients who are chronically hypoxic and have systemic hypertension. (Circulation 1989;79:337- 
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In this study, we tested the hypothesis that hypoxic pulmonary vasoconstriction may be enhanced in systemic hypertension. The hypothesis took origin from the following two considerations: alveolar hypoxia constricts the pulmonary vessels by enhancing the Ca2+ penetration across sarcolemma of the smooth muscle cells and systemic high blood pressure is associated with an elevation of tone and reactivity of the lung vessels, which seems to depend on an excessive cytosol free Ca21 concentration due to alterations in sodium handling and in the Na+-Ca2' exchange system. These considerations suggest the possibility that the disorders in the biochemistry of smooth muscle contraction in hypertension facilitate the rise of cytosol Ca2' concentration during alveolar hypoxia, thus resulting in a potentiation of the vasoconstrictor properties of this stimulus. In 43 hypertensive and 17 normotensive men, pulmonary arteriolar resistance has been evaluated during air respiration and after 15 minutes of breathing 17%, 15% , and 12% oxygen in nitrogen. Curves relating changes in pulmonary arteriolar resistance to oxygen breathing contents had similar configuration in the two populations but in hypertension were steeper and significantly shifted to the left, reflecting a lower threshold and an enhanced reactivity. This pattern was not related to differences in severity of the hypoxic stimulus, plasma catecholamine concentration, or hypocapnia and respiratory alkalosis induced by hypoxia and probably was not mediated through a-receptor activation. Calcium channel blockade with nifedipine was able to almost abolish both the normotensive and the hypertensive pulmonary vasoconstricting reaction. These findings support the hypothesis that hypoxic pulmonary vasoconstriction may be enhanced in systemic hypertension. As to the mechanism of this effect, findings are consistent with the interpretation that hypoxic vasomotion is mediated by an increased availability of calcium ions for the contractile elements of the lung vessels, which is facilitated with hypertension. The association of high blood pressure with enhanced pulmonary vasoreactivity to alveolar hypoxia could have clinical implications in patients who are chronically hypoxic and have systemic hypertension. (Circulation 1989;79:337-343) Alveolar hypoxia is a physiologic stimulus that causes local vasoconstriction of the pulmonary arteries, probably by affecting excitation, contraction, or the coupling of the two' A role of increased slow channel calcium entry into vascular smooth muscle in mediating pulmonary vasoconstriction is suggested by the observation that verapamil inhibits such vasoconstriction2 and that nifedipine reduces pulmonary vascular resistance in patients with respiratory failure. 3'4 Systemic primary hypertension is another clinical condition in which handling of Ca2' by the smooth muscle cell seems to be involved in the enhancement of the contractile activity of the lung vessels. In fact, the elevation of vascular pressure and resistance of the lesser circulation,5'7 compared with normal8; the hypersensitivity to catecholamines9; and the hyperreactivity of the lung vessels to sympathetic nervous system activation'0 11 that characterize systemic high blood pressure seem to depend on an excessive free calcium availability for smooth muscle contraction.12,13 Abnormalities in Na+ transport in essential hypertension would lead to intracellular Na' accumulation causing a decrease of movement of Ca2+ out of the cell through the Na+-Ca2+ exchange system resulting in an increase in intracellular Ca2+ and contractility.14 Thus, hypertension might be seen as a background facilitating the increase in the cytosol free Ca21 concentration during alveolar hypoxia and augmenting the vasoconstricting potency of this stimulus.
In the present study, we investigated the vasomotor responses to breathing of low oxygen mixtures in hypertensive and normotensive subjects and proved that hypoxic pulmonary vasoconstriction is enhanced in 16 Most of the testing sessions occurred in the morning, 1 week after admission to the hospital and after the patients had been familiarized on 3 consecutive days with the investigators, equipment, and environment. They were instructed to not smoke or ingest alcohol or caffeine-containing foods for 24 hours before testing. Observations were started 30 minutes after completion of right heart catheterization.
Methods
For convenience in presentation, the study has been subdivided into three parts. Part 1. Observations were made on 21 hypertensive and 10 normotedsive subjects. They consisted of a comparison of the systemic and pulmonary hemodynamic pattern of the two groups before and during breathing of low oxygen mixtures. An open circuit was used to administer ambient air or specific mixtures and consisted of a mouthpiece; a three-way, low dead space valve; and a Tissot gasometer. Each study consisted of five consecutive periods: ambient air breathing (control period) and four periods of 15 minutes of breathing 20%, 17%, 15%, and 12% oxygen in nitrogen. Between periods, the subjects were disconnected from the open circuit for 15-20 minutes of relaxation and ambient air breathing. Continuous records of heart rate (cardiotachograph) and systemic and pulmonary pressures were obtained throughout the studies. Cardiac output and pulmonary wedge pressure were measured, and systemic and pulmonary arteriolar resistance were calculated immediately before and at the end of each of the five periods. Hemodynamic variables between each breathing step returned to levels similar to those recorded at the beginning of the study, which indicated that between tests the steady state could be reestablished. During cardiac output evaluation, samples of peripheral arterial blood were withdrawn for the determination of the gaseous composition, pH, and concentration of catecholamines.
Part 2. In 16 other hypertensive and seven other normotensive subjects, we investigated the hemodynamics of the lesser circulation during low oxygen breathing, before and after nifedipine. The calcium antagonist was administered sublingually (20 mg), and the repeated series of tests were begun at least 30 minutes later, a time at which a known hemodynamic effect (decrease in arterial pressure) had occurred. The sequence of administration of specific breathing mixtures as well as the hemodynamic and humoral measurements in these patients were identical with those described above, with the exception of the 20% oxygen step. Figure 2 ) as well as of the epinephrine and norepinephrine plasma concentrations (Table 1) . Calcium Channel Blockade These observations were made on patients described in part 2 of "Methods." Before nifedipine, the finding was duplicated of enhanced hypoxic pulmonary vasoconstriction in hypertension, with increases in pressure and resistance (left side of Figure 3 ) significantly greater than in normotension at each step of low oxygen breathing. About 30 minutes after the administration of nifedipine (Table  2) , systemic blood pressure, vascular resistance, and plasma epinephrine concentration had diminished significantly; heart rate, cardiac index, and concentration of plasma norepinephrine had risen; and arterial blood gases and pH were unchanged in each group. Under the influence of the calcium channel blocker, pulmonary arterial pressure in hypertensive patients had fallen from an average of 16.2 to 12.7 mm Hg and arteriolar resistance from 84 to 52 dynes/sec/cm 5; their variations in normotensive subjects were minimal and statistically not significant. In each group, the curves representing changes from baseline of these variables during the hypoxic tests became flat, and those of hypertension were almost superposable on those of normotension (right side of Figure 3 ), indicating that resistance of lung vessels was reduced to similar levels after nifedipine. Hypoxic variations of blood flow through the lungs were minimal and similar to those before calcium channel blockade.
Although blood viscosity and lung mechanics were not studied, it is likely that neither varied importantly because hematocrit (44±3%) did not change and the amplitude of swings in the intrathoracic pressure, as measured in pulmonary wedge pressure recordings, after nifedipine was identical with that during the control period (12 ± 2 mm Hg).
a-Adrenergic Receptor Blockade
This part of the study was performed on only six hypertensive subjects in consideration of the reproducibility of our findings.
In the control condition, mean pulmonary arterial pressure rose by an average of 2.5 ± 2, 3.9 ± 1.8, and 6.1±2.2 mm Hg at the 17%, 15%, and 12% oxygen breathing periods, respectively; the corresponding average changes in pulmonary arteriolar resistance were + 12 ± 7, + 18 ± 8, and + 32 ± 6 dynes/ sec/cm 5. After phenoxybenzamine, cardiac index augmented by an average of 550 ml/min/M2, pulmonary arteriolar resistance was 19 dynes/sec/ cm-5 lower than in the control condition and mean pulmonary arterial pressure remained steady. Without exception, the hypoxic pulmonary vasomotor response persisted and increases in pressure and resistance were comparable to those recorded before a-adrenergic receptor blockade.
Discussion
The major finding in this study is that hypoxic pulmonary vasoconstriction is enhanced in high blood pressure and the threshold of the constrictor reaction is lowered. This suggestion is based on the -100 tomic changes involved the lung vessels, they could explain the enhancement of hypoxic pulmonary vasoconstriction during hypoxia observed in this study. However, although an increase of the pulmonary artery medial thickness has been reported in spontaneous hypertensive rats,27 there is no information in human subjects concerning the structure of the vessels in the lesser circulation in hypertension. Therefore, the question of whether an increased wall thickness and a reduced arterial lumen may be the cause of the augmented hypoxic vasoconstrictor reaction in hypertension remains basically unanswered. From these considerations the reasons for the enhancement of the hypoxic pulmonary vasoconstriction in hypertension seem referable to a potentiation of the contractile mechanisms of the pulmonary vascular smooth muscle rather than to neurogenic effects, mechanical factors, a-adrenergic receptor activation, or structural changes of the arterial wall.
We interfered with the vascular contractile activity through the calcium channel blocker nifedipine. This drug substantially reduced the vasomotor response to the hypoxic stimulus in both the normotensive and hypertensive subjects and abolished almost completely the differences in vasoconstriction between the two groups. However, we failed to identify, through this method, the exact mechanism by which hypertension enhances the potency of the hypoxic stimulus. In fact, the depression produced by nifedipine might reflect either an interference of the calcium channel blocker2-4,28 with the basic factors that mediate the rise in pulmonary vascular resistance, thus preventing any possibility of potentiation, whatever the mechanism through which hypertension causes this effect, or a nonspecific result of two opposing influences, vasodilating by nifedipine and vasoconstricting by hypoxia, on the vascular smooth muscle tone, or an antagonistic action on Ca21, whose transport across sarcolemma is facilitated by the hypoxic stimulus and whose availability for contraction is potentiated in hypertension. Our experiments neither support nor refute each of these interpretations.
Despite this limitation, the observation that patients with systemic hypertension have enhanced pulmonary vasoreactivity to acute alveolar hypoxia may have clinical significance for patients who have systemic hypertension and are chronically hypoxic.
